Zevra Therapeutics
ZVRA
32 hedge funds and large institutions have $30.1M invested in Zevra Therapeutics in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 3 closing their positions.
69% more capital invested
Capital invested by funds: $17.8M → $30.1M (+$12.3M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
11% less funds holding
Funds holding: 36 → 32 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$501K |
| 2 |
BlackRock
New York
|
+$329K |
| 3 |
Morgan Stanley
New York
|
+$97.6K |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$63.4K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$38.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$152K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$59K |
| 3 |
Millennium Management
New York
|
-$44.3K |
| 4 |
MC
Menta Capital
San Francisco,
California
|
-$23.5K |
| 5 |
Barclays
London,
United Kingdom
|
-$9.9K |
ZVRA Hedge Fund Activity: Q1 2017 in Review
32 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2017, worth a combined $30.1M — up 69% from $17.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ZVRA positions and 3 closed out — a net gain of 1 holder — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $501K. The largest seller was Federated Hermes, cutting an estimated $152K.
- 32 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2017, down from 36 in Q4 2016.
- Funds reported $30.1M of Zevra Therapeutics stock for Q1 2017, up 69% quarter-over-quarter.
- 4 funds opened new Zevra Therapeutics positions in Q1 2017 and 3 closed out, a net change of +1 holder.
- The largest Zevra Therapeutics buyer in Q1 2017 was Victory Capital Management, an estimated $501K added.
- The largest Zevra Therapeutics seller in Q1 2017 was Federated Hermes, an estimated $152K sold.
Based on aggregated 13F filings for Q1 2017.